Literature DB >> 3140157

Tissue plasminogen activator treatment of postoperative intraocular fibrin.

R N Johnson1, K Olsen, E Hernandez.   

Abstract

Intraocular recombinant tissue-type plasminogen activator was used for treatment of postoperative intraocular fibrin clots. Using a rabbit vitrectomy and cyclocryotherapy model of postoperative fibrin, rabbits were randomized on the first postoperative day to receive either an anterior chamber injection of lactated Ringer's solution or 25,000, 50,000, or 100,000 IU tissue plasminogen activator (tPA). An intraocular dose of 25,000 IU of tPA produced marked resolution of the fibrin clot 24 hours later. A 50,000 and 100,000 IU dose produced slightly more resolution of the fibrin. No ophthalmoscopic or histologic evidence of intraocular toxicity was seen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3140157     DOI: 10.1016/s0161-6420(88)33140-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

Review 1.  The pars plana incision: experimental studies, pathologic observations, and clinical experience.

Authors:  A E Krieger
Journal:  Trans Am Ophthalmol Soc       Date:  1991

2.  Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis.

Authors:  N Baziuk; T Fang; G A Peyman; C M Gremillion
Journal:  Int Ophthalmol       Date:  1991-03       Impact factor: 2.031

3.  Pars plana incisions of four patients: histopathology and electron microscopy.

Authors:  F H Koch; A E Kreiger; M Spitznas; B Glasgow; R Y Foos; M O Yoshizumi
Journal:  Br J Ophthalmol       Date:  1995-05       Impact factor: 4.638

4.  Experimental adhesion prophylaxis with recombinant tissue plasminogen activator.

Authors:  M N Vipond; S A Whawell; D M Scott-Coombes; J N Thompson; H A Dudley
Journal:  Ann R Coll Surg Engl       Date:  1994-11       Impact factor: 1.891

Review 5.  Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.

Authors:  G A Stern
Journal:  Trans Am Ophthalmol Soc       Date:  1993

Review 6.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

7.  The use of tissue plasminogen activator in post-traumatic total hyphaema.

Authors:  L Laatikainen; J Mattila
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-01       Impact factor: 3.117

8.  Recombinant tissue plasminogen activator following paediatric cataract surgery.

Authors:  J S Mehta; G G Adams
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

9.  Corneal endothelial permeability in protection glaucoma filter bleb with tissue plasminogen activator.

Authors:  A Szymanski; A Gierek-Lapinska; M Koziak; S Gierek-Kalicka
Journal:  Int Ophthalmol       Date:  1995       Impact factor: 2.031

10.  Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.

Authors:  A Heiligenhaus; B Steinmetz; R Lapuente; P Krallmann; C Althaus; W K Steinkamp; B Dick
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.